

**CURRICULUM VITAE**  
**WILLIAM VIRGIL BROWN, M.D.**  
**Charles Howard Candler Professor Emeritus**  
**Emory University School of Medicine**

Place of Birth: Royston, Georgia  
Marital Status: Married, (Alice), two sons

Office Address: 3208 Habersham Rd. NW  
Atlanta, Georgia 30305

Contact information: Telephone#: (404) 266 9006 Mobile #: (404) 909 2095  
Fax#: (404) 841 5623  
E-mail : [wbrow925@bellsouth.net](mailto:wbrow925@bellsouth.net)  
[editorjcl@lipid.org](mailto:editorjcl@lipid.org)

Office Support : Alice Brown (404) 909 0227  
[wbrow925@bellsouth.net](mailto:wbrow925@bellsouth.net)

**EDUCATION**

June, 1960 B.A., Emory University, Atlanta, Georgia  
June, 1964 M.D., Yale University, New Haven, Connecticut

**PROFESSIONAL EXPERIENCE**

1964-1966 Intern and Assistant Resident, Osler Medical Service, Johns Hopkins Hospital, Baltimore, Maryland

1966-1969 Clinical Associate, National Heart and Lung Institute National Institutes of Health, Bethesda, Maryland

1969-1970 Fellow in Endocrinology and Metabolism, Yale University School of Medicine, New Haven, Connecticut

1970-1974 Assistant Professor of Medicine, Division of Metabolic Disease, Department of Medicine, University of California, San Diego, La Jolla, California

1974-1978 Associate Professor of Medicine, Division of Metabolic Disease, Department of Medicine, University of California, San Diego, La Jolla, California

1978-1987 The Joseph Lowe and Lewis Price Professor of Medicine, Chief, Division of Arteriosclerosis & Metabolism, Department of Medicine, Mount Sinai School of Medicine, New York, New York

1987-1991 President and CEO, Medlantic Research Foundation, Washington, D.C.

1991-1998 Chief of the Division of Arteriosclerosis and Metabolism, Emory University School of Medicine  
1991-2009 Charles Howard Candler Professor of Medicine, Emory University

1998–2003 Chief, Medicine and Primary Care Service, Atlanta, VA Medical Center

2003-2009 Chief, Medical Specialty Care Service Line, Atlanta VA Medical Center

2007- Present Editor in Chief Journal of Clinical Lipidology

2009 Present Charles Howard Candler Professor of Medicine Emeritus, Emory University

## **HONORS**

Phi Beta Kappa

Alpha Omega Alpha

Chairman of Faculty, UCSD School of Medicine (1977-1978)

Joseph Lowe and Louis Price Professor of Medicine, Mt. Sinai School of Medicine (1979)

Alexander Von Humboldt Prize, Senior Research Fellowship to the University of Cologne, 1985

Distinguished Professor of the Year Award (1987) Mount Sinai School of Medicine

National President, American Heart Association (1991-1992)

Charles Howard Candler Professor of Internal Medicine (1991)

Address at Graduation Ceremony for Emory College, 1993 Oxford Georgia.

American Heart Association Gold Heart Award (1996)

President, South East Lipid Association, (1997-99)

President, Emory University Senate 1998-1999

Master Physician Award, American College of Physicians (1999)

R. Bruce Logue Award for Lifetime Contribution to Medicine (2000)

President National Lipid Association (2002- 2004)

President of the National Board of Clinical Lipidology (2004-2008)

Distinguished Achievement Award (2008) from Emory Medical Alumni

Distinguished Achievement Award from National Lipid Association 2009

Outstanding Achievement Award at International Symposium on Atherosclerosis 2009

President of the International Atherosclerosis Society (2009 -2012)

The Annual Keynote Address at the Southeast Lipid Research Conference designated as the William Virgil Brown Lecture.

Karl P. Klassen Lecturer, Ohio State Medical Center (2010)

Mona Shimshi Memorial Lecturer, Mount Sinai School of Medicine (2011)

Significant Sig Award, National Award from Sigma Chi Fraternity

## **RESEARCH INTERESTS**

Study of the structure and metabolism of lipoproteins.

Study of the lipolytic enzymes, including their molecular and kinetic characteristics.

Diagnosis and treatment of the hyperlipoproteinemias.

The relationship of lipoprotein metabolism to atheromatous vascular disorders.

Clinical trials of drugs affecting lipid metabolism

Clinical Observational Studies Related to Risk Factors for Cardiovascular Disease

**1.**

**2. CLINICAL INTERESTS**

Delivery of Preventive Health Care in CV Disease

Disorders of lipid transport

Atheromatous vascular disease

Diabetes mellitus

Nutrition

### **BOARD STATUS**

1972           Diplomate, Internal Medicine, American Board of Internal Medicine.  
1972           Diplomate, Subspecialty of Endocrinology, American Board of Internal Medicine.  
1995           Diplomate, American Board of Bioanalysis  
                  (Qualified as Director of High Complexity Clinical Laboratory)  
2006           Diplomate, American Board of Clinical Lipidology.

### **MEMBERSHIPS**

Organizations:

Fellow, Arteriosclerosis Council, American Heart Association  
Fellow, Epidemiology and Preventive Cardiology Council, AHA  
Fellow, American College of Physicians  
American Federation of Clinical Research  
American Heart Association  
American Society of Clinical Investigation  
American Society of Experimental Biology  
National Lipid Association

### **DEPARTMENT FUNCTIONS**

**University of California, San Diego:**

1970-78           Attending Physician, University Hospital  
1972-75           Director of Housestaff Recruitment Committee, Dept. of Medicine  
1972-78           Director of Lipid Research Clinic, University Hospital  
1973-78           Attending Physician, San Diego VA Hospital  
1974-76           Chief of Diabetes Clinic, University Hospital

**Mount Sinai School of Medicine, New York, NY**

1978-1987        Professor of Medicine, City University of New York  
1978-87           Attending Physician, Medical Service, Mount Sinai Hospital,  
                  and the Bronx Veterans Administration Medical Center  
1978-87           Chief, Division of Arteriosclerosis and Metabolism

**Emory University School of Medicine, Atlanta, GA**

1991-Present     Director, Section on Arteriosclerosis and Lipid Metabolism - Emory Clinic  
1991-2003        Director, Division of Arteriosclerosis and Lipid Metabolism - School of  
                  Medicine  
2003-Present     Director of Lipids Section, (Division of Endocrinology, Metabolism and Lipids).  
1991-98           Faculty, Graduate School of Nutrition  
1996-2006        Chairman, GCRC Advisory Committee (GAC),

### **UNIVERSITY SERVICE**

**University of California, San Diego:**

1972-74           Chairman, House Staff Selection Committee  
1974-75           Chairman, Elective Committee

1975-76 Chairman, Curriculum Committee  
1976-77 Vice Chairman of Faculty  
1977-78 Chairman of Faculty, School of Medicine

**Mount Sinai School of Medicine, NY, New York**

1978-87 House Staff Selection Committee  
1980 Search Committee: Chairman of Obstetrics/Gynecology; Chief, Section of Cardiology, Department of Medicine  
1980-87 House Staff Advisory Committee, Department of Medicine  
1983-85 Research Advisory Committee to the Dean  
1984-87 Research Review Committee, Department of Medicine  
1984-87 Mount Sinai Molecular Biology Center Steering Committee  
1985-87 Institutional Animal Care and Use Committee

**Emory University:**

1995-Present Clinical Research Center (GCRC) Advisory Committee  
1996-97 University Senate, Representative from Medical School  
1997-98 Vice Chairman, University Senate  
1998-99 President, Faculty Council  
1998-99 President, University Senate  
1998-2006 Chairman, GCRC Advisory Committee  
2002-2006 School of Medicine Faculty Relations Committee

**EXTERNAL COMMITTEE SERVICE**

1977-81 Editorial Board, Journal of Lipid Research  
1978-80 Metabolism Study Section, National Institutes of Health  
1978-80 Physiology Study Section, American Heart Association  
1978-80 Credentials Committee, Arteriosclerosis Council, AHA  
1979-81 Executive Committee, N.Y. Heart Association  
1979-82 Chairman, Credentials Committee, Arteriosclerosis Council, AHA  
1979-83 Chairman, Diet Committee, N.Y. Heart Association  
1980-81 Chairman, Metabolism Study Section, NIH  
1981-87 Board of Directors, New York Heart Association  
1981-86 Nutrition Committee, American Heart Association  
1981-82 New York Lipid Club Chairman  
1981-82 Lipid Metabolism Task Group, NHLBI  
1982-86 Chairman, Nutrition Committee, American Heart Association  
1983 Peer Review Research Committee, American Heart Association, New York State Affiliate  
1983 Board of Directors, American Heart Association  
1983 External Advisory Committee, SCOR on Arteriosclerosis, LSU  
1983 External Advisory Committee, Program Project on Lipoprotein Metabolism, Pritzker School of Medicine, University of Chicago Task Force on Post Graduation Education Programs,  
1983-84 Task Force on Risk Factor Reduction at the Worksite, American Heart Association  
1983-86 Advisory Committee to NHLBI on Arteriosclerosis, Hypertension and Lipid Metabolism

1984 Chairman of Gordon Conference on Lipid Metabolism  
 1984-85 Strategic Issue Groups, American Heart Association  
 1984-85 Steering Committee for Medical and Community Programs, American Heart Association  
 1984-85 Nominating Committee, New York Heart Association  
 1984-86 Research Advisory Committee, Juvenile Diabetes Foundation  
 1984-87 Chairman, Ad Hoc Committee on Nutrition and Lipid Metabolism, NHLBI  
 1984-87 Chairman, Ad Hoc Committee on Diabetes and Vascular Disease, NHLBI  
 1985 Medical Advisory Panel, Citizen's for Public Action on Cholesterol  
 1985-87 Chairman, Awards Committee, Arteriosclerosis Council, American Heart Association  
 1986 Chairman, Task Force on Socioeconomic Status and Risk Factors, American Heart Association  
 1986 Task Force on Product Licensing and Endorsement, American Heart Association  
 1986-1987 National Cholesterol Education Program, Adult Treatment Panel, Co-chairman Dietary Subcommittee  
 1987 Organizer, Phoenix Conference on Dietary Composition (Feb 19-21) and Apolipoprotein Metabolism, 1987-1991 Co-Chairman, Medical Advisory Board, Countdown, USA  
 1987-1989 Education and Community Programs Committee, Vice Chairman, American Heart Association.  
 1988 Chairman, Conference on Sucrose Polyester, Washington, D.C.  
 1988-1991 Board of Directors, American Heart Association, Nation's Capital Affiliate  
 1988-1991 Budget and Finance Committee, American Heart Association  
 1988-1994 Asymptomatic Carotid Artery Plaque Study Policy Data and Safety Monitoring Board (PLACII).  
 1988-1994 Pravastatin, Lipids, and Atherosclerosis in the Coronary Arteries (PLAC I) Policy, Data and Safety Monitoring Board.  
 1988-1990 Secretary and Treasurer D.C. Cardiovascular and Renal Education Consortium (D.C. Care)  
 1989-1990 Committee on the Nutrition Components of Food Labeling. Institute of Medicine, National Academy of Sciences.  
 1989-1994 National Board of Directors, American Heart Association  
 1990-1991 President-Elect, American Heart Association  
 1990-1991 Chairman - Awards Committee, National High Blood Pressure and Cholesterol Conference, Washington, D.C. April, 1991.  
 1991-1995 Editorial Board, Journal Of Lipid Research  
 1991-1992 National President, American Heart Association  
 1992-1996 Steering Committee of National Partnership in Nutrition  
 1994-1998 Coronary Artery Disease:Index & Reviews, Editor-in-Chief  
 1995-1998 Safety and Data Monitoring Committee, AVERT Study (Parke-Davis)  
 1996-1998 Bristol-Myers Squibb Cardiovascular Advisory Board  
 1996-1998 Parke-Davis Consultants Board for Development of Atorvastatin  
 1996-2005 Board of Directors, Fulton County American Heart Association  
 1996-1998 Chairman, Organizing Committee-S.E. Lipid Association  
 1998-1999 President, South Lipid Association  
 1998-2002 Chairman, Data Safety Monitoring Committee-PROSPER Study  
 1998-2006 Data Safety Monitoring Committee-TNT Study  
 1998-2005 Safety and Data Monitoring Committee A to Z Study  
 2002-2004 President, National Lipid Association (Founding Member)  
 2002-2007 National Chairman, Conflict of Interest Committee –American Heart Association

2004-2008 President, National Board of Clinical Lipidology

The following have worked in **Dr. Brown's laboratory in training status or on sabbatical:**

<u>Name</u>	<u>Status</u>	<u>Present Position</u>
Heiner Greten, M.D.	Visiting Professor, 1972	Chief of Medicine Emeritus University-Krankenhaus Eppendorf, Hamburg, West Germany
Christian Ehnholm, M.D.	Postdoctoral Fellow, 1972-1973	Professor of Immunology, Univ. of Helsinki
Walter Shaw, Ph.D.	Doctoral Candidate, Collaborative Research, University of Alabama, 1973	President, Avanti Chem. Company Birmingham, AL
Jonas Boberg, M.D.	Visiting Professor, 1973-1974	Professor of Gerontology & Medicine, University of Uppsala, Uppsala, Sweden
Jan Augustin, M.D.	Postdoctoral Fellow, 1973-1975	President of pharmaceutical company, Germany
Gert Middelhoff, M.D.	Postdoctoral Fellow, 1973-1974	Physician in Government Service, Germany
Adolfo Correa, M.D.	Doctoral Candidate (M.D.), 1973-1974	Private Practice, Internal Medicine
Brian Roach, M.D.	Doctoral Candidate (M.D.), 1975	Private Practice, Internal Medicine
Hudson Freeze, Ph.D.	Postdoctoral Fellow, 1976-1978	Professor, Burnham Institute Lajolla, California
Ngoc-Anh Le, Ph.D.	Doctoral Candidate (Ph.D), 1973-1975	Associate Professor of Medicine - Em University School of Medicine
Henry Ginsberg, M.D.	Research Fellow, 1976 Clin. Instructor In Med. 1977-1978 Assist. Professor of Med. 1978-1984	Professor of Medicine Columbia Univ., College of Physicians & Surgeons
Ira Goldberg, M.D.	Postdoctoral Fellow, 1979-1981	Professor of Medicine Columbia Univ., College of Physicians & Surgeons
Phillip Bukberg, M.D.	Postdoctoral Fellow, 1979-1982	Senior Physician, St. Vincent's Hospital New York, New York
Tania Martinez, M.D.	Visiting Professor,	Prof. of Molecular

	1979-1981	Biology, Escola Paulista Medicina Sao Paulo, Brazil
Edmund Giegerich, M.D.	Postdoctoral Fellow, 1980-1981	Physician in Charge - Endocrinology, The Long Island College Hospital Brooklyn, New York
Ellen Gitler, M.D.	Postdoctoral Fellow, 1981-1983	Director of Diabetes and Lipid Clinic, N. Central Bronx Hospital, Bronx, New York
David Gorson, M.D.	Postdoctoral Fellow, 1984-1986	Private Practice North Miami Beach, Florida
Mona Shimshi, M.D.	Postdoctoral Fellow, 1985-1987	Staff Physician - Meta- bolism and Endocrinology Elmhurst Medical Center
Ardon Rubinstein M.D.	Visiting Scientist	Clin. Prof. Directore of Lipid Clinic Sackler School of Medicine, Tel Aviv, Israel
Mark Horowitz, M.D.	Postdoctoral Fellow, 1986-1987	Private Practice of Medicine
Antonella Bianchi, M.D.	Postdoctoral Fellow, 1986-1987	Assistant Professor of Medicne Southern Florida School of Medicine Tampa, Florida
Laszlo Tornoci, M.D.	Postdoctoral Fellow, Fogerty Fellowship 1988-1990.	Professor of Med. Inst. of Pathophysiology Femmelweis University Medical School Budapest, Hungary.
Hajime Ide, M.D.	Visiting Scientist 1988-1989	Professor of Medicine, Hokkaido Univ., Sapporo, Japan
Laraine Field, M.D.	Postdoctoral Fellow, 1987-1991	Private Practice of Medicine Washington, D.C. Emory University
Laura Klug	Thesis Advisor (MPH) Nutrition 1992-1994	School of Public Health Atlanta, GA
Teo Chumburidze	Graduate Student (MPH) Coronary Heart Prevention 1995-1996	Emory University School of Public Health Dept. of Int'l Health Atlanta, GA

Najat Yahia PhD.	Visiting Professor Summer 1999-2001	University of Notre Dame, Beirut
Gocha Saliashvili M.D.PhD.	Postdoctoral Fellow 2001-2002	Fellow Assistant Professor in Cardiology U. of Texas, Galveston
David Arveladze M.D. PhD.	Postdoctoral Fellow 2001-2002	Resident Physician at U of Ohio
Jennifer Lee M.D.	Postdoctoral Position 1999-2000	Private Practice of Endocrinology
Quinton Gradek M.D.	Postdoctoral Position 1999-2000	Fellow in Cardiology, Emory University
Matthey Harris, MD	PGY5 Postdoctoral Fellow 2002-Present	Private Practice in Endocrinology
Mohamad Moussa, MD	Post Doctoral Fellow 2002 - 2005	Assistant Professor of Medicine and Geriatrics Emory University School of Medicine
Sheila Gupta, MD	Post Doctoral Fellow 2005 -2007	Private Practice of Endocrinology Research Fellow
Anil Mathew, MD	Post Doctoral Fellow 2005 -2007	Private Practice of Endocrinology



## PEER REVIEWED PUBLICATIONS

1. LaRosa, J.C., Brown, W.V. Glueck CJ, Levy RI Fredrickson DS. 1969. Clofibrate-induced ventricular arrhythmia. Am. J. Cardiol., 23: 266-269.
2. Glueck, C.J., Brown, W.V. et al. 1969. Amelioration of hypertriglyceridemia by progestational drugs in familial Type V hyperlipoproteinemia. Lancet, 1: 1290-1291.
3. Glueck CJ, Brown WV, Greten H, Levy RI Fredrickson DS. 1969. Treatment of Hypertriglyceridemia. Lancet 2 (7625):852.
4. Brown, W.V., Levy, R.I. and Fredrickson, D.S. 1969. Studies of the proteins in human plasma very low density lipoproteins. J. Biol. Chem., 244: 5687-5694.
5. Brown, W.V., Levy, R.I. and Fredrickson, D.S. 1970. Further separation of the apoproteins of the human plasma very low density lipoproteins. Biochim. Biophys. Acta, 200: 573-575.
6. Mahley, R.W., Bersot, T.P., Lequire, V.S., Levy, R.I., Windmueller, H.G. and Brown, W.V. 1970. Identity of very low density lipoprotein apoproteins of plasma and liver Golbi apparatus. Science, 168: 380-382.
7. Bersot, T.P, Brown, W.V. et al. 1970. Further characterization of the apolipoproteins of rat plasma lipoproteins. Biochem., 9: 3427-2432.
8. Brown, W.V., Levy, R.I. and Fredrickson, D.S. 1970. Further characterization of apolipoproteins from the human plasma very low density lipoproteins. J. Biol. Chem., 245: 6588-6594.
9. Fellig, P., Brown, W.V., Levine, R.A. and Klatskin, G. 1970. Glucose Homeostasis in viral hepatitis. New Engl. J. of Med., 283: 1436-1440.
10. LaRosa, J.C., Levy, R.I., Brown, W.V. and Fredrickson, D.S. 1971. Changes in high density lipoprotein composition after heparin induced lipolysis. Am. J. Physiol., 220: 785-791.
11. Lee, R.V., Jampol, L. and Brown, W.V. 1971. Nephrogenic diabetes insipidus and lithium intoxication – complications of lithium carbonate therapy. New Engl. J. Med., 284: 93-94.
12. Gotto, A.M., Brown, W.V. et al. 1972. Evidence for the identity of the major apoprotein in low density and very low density lipoproteins in normal subjects and patients with familial hyperlipoproteinemia
  - a. J. Clin. Invest.51: 1468-1494.
13. Brown, W.V. and Baginsky, M.L. 1972. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem. Biophys. Res. Commun., 46: 375-382.

14. Greten, H., Walter, B. and Brown, W.V. 1972. Purification of human postheparin plasma triglyceride lipase. FEBS Letters, 27: 306.
15. Brown, W.V. and Greten, H. 1973. Type I hyperlipoproteinemia. Clin. in Endo. and Metab., 2: 73-80.
16. Levy, R.I., Fredrickson, D.S., Stone, N.J., Bilheimer, D.W., Brown, W.V. et al. 1973. Cholestyramine in Type II hyperlipoproteinemia: A double-blind trial. Ann. Int. Med., 79: 51-58.
17. Bensadoun, A., Ehnholm, C., Steinberg, D. and Brown, W.V. 1974. Purification and characterization of lipoprotein lipase from pig adipose tissue. J. Biol. Chem., 249: 2220-2227.
18. Sniderman AD. Chandler JG. Steinberg D. Brown WV. 1974. Evidence for the hepatic origin of a canine post-heparin plasma triglyceride lipase. FEBS Letters. 42(2):157-60,
19. Ehnholm, C., Greten, H. and Brown, W.V. 1974. A comparative study of postheparin lipolytic activity and a purified human plasma triglyceride lipase. Biochem. Biophys. Acta, 360: 68-77.
20. Greten, H., Sniderman, A.D., Chandler, J.G., Steinberg, D. and Brown, W.V. 1974. Evidence for the hepatic origin of a canine postheparin plasma triglyceride lipase. FEBS Letters, 42: 157-160.
21. Cottrill, C., Glueck, C.J., Leuba, V., Millett, F., Puppione, D. and Brown, W.V. 1974. Familial homozygous hypobetalipoproteinemia. Metabolism, 23: 779.
22. Wetmore, S., Mahley, R.W., Brown, W.V. and Schachter, H. 1974. Incorporation of sialic acid into sialidase-treated apolipoprotein of human very low density lipoprotein by a pork liver sialyltransferase. Can. J. Biochem., 52: 655.
23. Brown WV. Baginsky ML. 1974. Some functional aspects of apolipoproteins: apoLp-Ala (**now APOCIII**) inhibition of lipoprotein lipase and deinhibition by monoolein. Hormone & Metabolic Research. Suppl 4:11-6.
24. Trauble, H., Middelhoff, G. and Brown, W.V. 1974. Interaction of a serum apolipoprotein with ordered and fluid lipid bilayers. Correlation between lipid and protein structure. FEBS Letters, 49: 269-275.
25. Ehnholm, C., Shaw, W., Greten, H. and Brown, W.V. 1975. Purification from human plasma of a heparin-released lipase with activity against triglyceride and phospholipids. J. Biol. Chem., 250: 6756-6761.
26. Middelhoff, G., Rosseneu, M., Peters, H. and Brown, W.V. 1976. Study of the lipid binding characteristics of the apolipoproteins from human high density lipoproteins: I. Electron microscopic and gel filtration studies with synthetic lecithins. Biochim. Biophys. Acta, 441: 57-67.
27. Rosseneu, M., Soetewey, V., Middelhoff, G., Peters, H. and Brown, W.V. 1976. Studies of the lipid binding characteristics of the apolipoproteins from human high density lipoproteins: I

- Calorimetry of the binding of apo-AI and apo-AII with phospholipid. Biochim. Biophys. Acta, 441: 68-80.
28. Baginsky, M.L. and Brown, W.V. 1976. Effects of monoolein on hydrolysis of triglyceride by lipoprotein lipase in the presence of an inhibitory apoprotein (**apoCIII**). Physiol. Chem. and Physics, 9: 197-206.
  29. Augustin, J. Middelhoff, G. and Brown, W.V. 1976. Metabolismus der lipoproteine. In: Fettstoffwechsel, (Springer-Verlag, Germany) 219-264.
  30. Augustin J. Freeze H. Tejada P. Brown WV. 1978. A comparison of molecular properties of hepatic triglyceride lipase and lipoprotein lipase from human post-heparin plasma. Journal of Biological Chemistry. 253(9):2912-20.
  31. Baginsky, M.L. and Brown, W.V. 1977. Differential characteristics of purified hepatic triglyceride lipase and lipoprotein lipase from human postheparin plasma. J. Lipid Res., 18: 423-437.
  32. Kwiterovich, P.O., Jr., Farah, J.R., Brown, W.V. et al. 1977. The clinical, biochemical and familial presentation of Type V hyperlipoproteinemia in childhood. Pediatrics, 58(4): 513-534.
  33. Ehnholm, C., Bensadoun, A. and Brown, W.V. 1977. Characterization of two triacylglycerol lipase activities in pig postheparin plasma. Biochem. J., 163: 347-355.
  34. Soeteway, F., Lievens, M.J., Vercaemst, R., Rosseneu, M., Peters, H. and Brown, W.V. 1977. Ionization behavior of native apoproteins and of their complexes with lecithin. Eur. J. Biochem., 79: 259-264.
  35. Boberg, J., Augustin, J., Baginsky, M.L., Tejada, P. and Brown, W.V. 1977. Quantitative determination of hepatic and lipoprotein lipase activities from human postheparin plasma. J. Lipid Res., 18: 544-547.
  36. Boberg, J., Boberg, M., Gross, R., Grundy, S., Augustin, J. and Brown, W.V. 1977. The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities from human postheparin plasma in male patients with hyperlipoproteinemia. Athero., 27: 499-503.
  37. Le., N.-A., Melish, J.S., Roach, B.C., Ginsberg, H.N. and Brown, W.V. 1978. Direct measurement of apoprotein-B specific activity in <sup>125</sup>I-labeled lipoproteins. J. Lipid Res., 19: 578-584.
  38. Baginsky, M.L., Wu., F. and Brown, W.V. 1978. Assay of lipoprotein lipase in postheparin plasma after suppression of the hepatic triglyceride lipase with sodium dodecyl sulfate. In: The Lipoprotein Molecule, Ed., Peters, H.; Proc. of a NATO Advance Study Inst. Meeting - Brugge, Belgium, May 8-20. (Plenum Publ. Co., New York) 15: 169-182.
  39. Barrett-Connor, E., Brown, W.V., et al. 1979. Heart disease risk factors and hormone use in postmenopausal women. J. Am. Med. Assn., 24: 2167-2169.
  40. Baginsky ML and Brown WV. 1979. A new method for the measurement of lipoprotein lipase in

postheparin plasma using sodium dodecyl sulfate for the inactivation of hepatic triglyceride lipase. J Lipid Res. 20:548-556.

41. Steinberg, D., Grundy, S.M., Mok, H.Y.I., Turner, J.D., Weinstein, D.B., Brown, W.V. and Albers, J.J. 1979. Metabolic studies in an unusual case of asymptomatic familial hypobetalipoproteinemia with hypoalphalipoproteinemia and fasting chylomicronemia. J. Clin. Invest., 64: 292-301.
42. Boberg, J, Boberg, M., Gross, R., Turner, J.D., Augustin, J. and Brown, W.V. 1979. Hepatic triglyceride and lipoprotein lipase activities of postheparin plasma in normals and hypertriglyceridemics. Uppsala J. Med. Sci., 84: 215-277.
43. Melish, J., Le, N.-A., Ginsberg, H., Steinberg, D. and Brown, W.V. 1980. Dissociation of apoprotein-B and triglyceride production in very low density lipoproteins. Am. J. Physiol., 239: E354.
44. Turner, J.D., Le, N.-A. and Brown, W.V. 1981. Effect of changing dietary fat saturation on low density lipoprotein metabolism in man. Amer. J. Physiol., 241: E57-63.
45. Ginsberg, H., Le, N.-A., Melish, H., Steinberg, D. and Brown, W.V. 1981. Effect of a high carbohydrate diet on apoprotein-B catabolism in man. Metabolism, 30: 347-353.
46. Gibson, J.C. and Brown, W.V. 1981. High density lipoprotein measurement - rationale and methodology. Lab Management, 19: 25-35.
47. Gilbert, H.S., Ginsberg, H., Faegerstrom, R. and Brown, W.V. 1981. Characterization of hypocholesterolemia in myeloproliferative disease. Am. J. Med., 71: 595-602.
48. Ginsberg, H., Le, N.-A., Mays, C., Gibson, J. and Brown, W.V. 1981. Lipoprotein metabolism in non-responders to increased dietary cholesterol. Arteriosclerosis, 1: 463-470.
49. Ginsberg, H., Gilbert, H., Gibson, J.C., Le, N.-A. and Brown, W.V. 1982. Decreased plasma low density lipoprotein cholesterol in subjects with myeloproliferative disorders: A state of increased lipoprotein catabolism. Ann. Int. Med., 96(3): 311-316.
50. Wang-Iverson, P., Ungar, A., Bukberg, P., Gibson, J. and Brown, W.V. 1982. Human monocytes in culture synthesize and secrete lipoprotein lipase. Biochim. Biophys. Res. Commun., 104: 923-928.
51. Ginsberg, H., Davidson, N., Le, N.-A., Gibson, J., Ahrens, E.H. and Brown, W.V. 1982. Effect of a portacaval shunt on lipoprotein synthesis and degradation in heterozygous familial hypercholesterolemia. Biochim. Biophys. Acta, 712: 250-257.
52. Goldberg, I.J., Le, N.-A., Paterniti, J.R., Ginsberg, H.N. and Brown, W.V. 1982. Effect of acute inhibition of hepatic triglyceride lipase on very low density lipoprotein metabolism in the cynomolgus monkey. J. Clin. Invest., 70: 1184-1192.
53. Brown, W.V., Bloomgarden, Z. and Ginsberg, H.N. 1982. Lipoproteins as risk factors for vascular disease in diabetes. Symposium: "Atherosclerosis and Diabetes" Eds., Ellenberg, M. and Brown, W.V. Mount Sinai J. Med., 49: 176-186.

54. Wang-Iverson, P. and Brown, W.V. 1982. Interaction of lipoprotein lipase with cultured endothelial cells. Ann. N.Y. Acad. Sci., 401: 92-101.
55. Grundy, S.M., Bilheimer, D., Blackman, H., Brown, W.V. et al. 1982. Rationale of the Diet Heart State of the American Heart Association. Circulation, 65: 839A-854
56. Goldberg, I., Paterniti, J.R., Franklin, B.H., Ginsberg, H., Ginsberg-Fellner, F. and Brown, W.V. 1983. Transient Type I hyperlipoproteinemia. Am. J. Med. Sci., 286: 28-31.
57. Goldberg, I.J., Le, N.-A., Ginsberg, H.N., Paterniti, J.R. and Brown, W.V. 1983. Metabolism of apoprotein-B in the cynomolgus monkey: Evidence for direct production of low density lipoprotein apoprotein-B. Amer. J. Physiol. (Endocrin. & Metab.), 244: E196-201.
58. Gibson, J. and Brown, W.V. 1983. Methods for quantitating human plasma apolipoproteins. Laboratory Management, 21: 19-28.
59. Paterniti JR, Jr, Brown WV, Ginsberg HN and Artz K. 1983. Combined lipase deficiency (CLD): a lethal mutation on chromosome 17 of the mouse. Science 221:167-169.
60. Ginsberg, H., Goldberg, I.J., Wang-Iverson, P., Gitler, E., Le, N.-A., Gilbert, H.S. and Brown, W.V. 1983. Increased catabolism of native and cyclohexanedione-modified low density lipoprotein in subjects with myeloproliferative diseases. Arteriosclerosis, 3: 233-241.
61. Bukberg, P., Le, N.-A., Gibson, J.C., Ginsberg, H. and Brown, W.V. 1983. Direct measurement of apoprotein-CIII specific activity in <sup>125</sup>I labeled very low density lipoproteins using immunoaffinity chromatography. J. Lipid Res., 24: 1251-1260.
62. Goldberg, I.J., Paterniti, J.R., Jr. and Brown, W.V. 1983. Detection and measurement of lipoprotein lipase and hepatic triglyceride lipase activities in the cynomolgus monkey. Biochim. Biophys. Acta, 752: 172-177.
63. Gibson, J.C., Rubinstein, A., Bukberg, P.R. and Brown, W.V. 1983. Apolipoprotein E enriched lipoprotein subclasses in normolipidemic subjects. J. Lipid Res., 24: 886-898.
64. Le, N.-A., Ginsberg, H.N. and Brown, W.V. 1984. Protocol for efficient plasma sampling for low density lipoprotein turnover studies. J. Lipid Res., 25: 1387-1391.
65. Gibson, J.C., Rubinstein, A. and Brown, W.V. 1984. ApoE containing lipoproteins by precipitation reagents for apolipoprotein B. Clinical Chemistry, 30: 1784-1788.
66. Bloomgarden, Z., Ginsberg-Fellner, F., Rayfield, J., Bookman, J. and Brown, W.V. 1984. Elevated hemoglobin A<sub>1c</sub> and low-density lipoprotein cholesterol levels in thiazide-treated diabetic patients. Am. J. Med., 77: 823-838.
67. Rubinstein, A., Gibson, J.C., Paterniti, J.R., Jr., Kakis, G., Little, A., Ginsberg, H.N. and Brown, W.V. 1985. The effect of heparin induced lipolysis on the distribution of apolipoprotein E among lipoprotein subclasses. J. Clin. Invest., 75: 710-721.
68. Wang-Iverson, P., Petaneau, L.A., Ginsberg, H.N., Le, N.-A. and Brown, W.V. 1985. ApoE-mediated uptake and degradation of normal very low density lipoproteins by human monocyte/macrophages: A saturable pathway distinct from the LDL receptor. Biochim. Biophys.

- Res. Commun., 126: 578-586.
69. Goldberg, I.J., Mazlen, R., Rubinstein, A., Gibson, J.C., Paterniti, J.R., Jr., Lindgren, F.T. and Brown, W.V. 1985. Plasma lipoprotein abnormalities associated with acquired hepatic triglyceride lipase deficiency. Metabolism, Clinical and Experimental 34: 832-835.
  70. Olivecrona, T., Chernick, S.S., Bengtsson-Olivecrona, G., Paterniti, J.R., Brown, W.V. et al. 1985. Combined lipase deficiency (cld/cld) in mice: Demonstration that an inactive form of lipoprotein lipase is synthesized. J. Biol. Chemistry, 260(4): 2552-2557.
  71. Ginsberg, H.N., Le, N.-A., Gordon, R.E., Goldberg, I.J. and Brown, W.V. 1985. Immunaffinity isolation of apolipoprotein E containing lipoproteins. Biochim. Biophys. Acta, 835: 113-123.
  72. Bukberg, P.R., Le, N.-A., Ginsberg, H.N., Gibson, J.C. and Brown, W.V. 1985. Metabolism of apolipoprotein C-III in man: Evidence for non-equilibrating pools. J. Lipid Res., 26: 1047-1057.
  73. Wang-Iverson, P., Gibson, J.C. and Brown, W.V. 1985. Plasma apolipoprotein E secretion by human monocyte-derived macrophages. Biochim. Biophys. Acta, 834: 256-262.
  74. Bershad, S., Rubinstein, A., Paterniti, J.R., Le, N.-A., Poliak, S.K., Keller, B., Ginsberg, H., Fleishmajer, R. and Brown, W.V. 1985. Changes in Plasma Lipids and Lipoproteins During Isotretinoin Therapy for Acne: a reappraisal. New Engl. J. Med., 313: 981-985.
  75. Gibson, J.C., Rubinstein, A., Brown, W.V. et al. 1985. Apolipoprotein E containing lipoproteins in low density or high density lipoprotein-deficient states. Arteriosclerosis, 5: 371-380.
  76. Brown, W.V. and Karmally, W. 1985. Coronary heart disease and the consumption of diet high in wheat and other grains. Am. J. Clin.Nutr., 41: 1163-1171.
  77. Ginsberg, H.N., Brown, W.V. and Goldberg, I.J. 1985. Treatment of common lipoprotein disorders. Primary Cardiology, 11: 152-166.
  78. Le, N.-A., Bukberg, P.R., Ginsberg, H.N., Gibson, J.C. and Brown, W.V. 1986. Direct determination of apoC-III specific activity using immunoaffinity chromatography. Methods of Enzymology, 129:457-468.
  79. Gibson, J.C., Rubinstein, A., Ginsberg, H.N. and Brown, W.V. 1986. Isolation of apoE containing lipoproteins by affinity chromatography. In: Methods in Enzymology, Eds., Albers, J. and Segrest, J. (Academic Press, New York) pp 186-200.
  80. Le, N.-A., Ramakrishnan, R., Dell, R.B., Ginsberg, H. and Brown, W.V. 1986. Kinetic analysis of specific radioactivity data. Methods of Enzymology, 129: 384-394.
  81. Faierman, D., Nechemias, C. and Brown, W.V. 1986. Electrocardiographic abnormalities in diabetes mellitus: association between T-wave changes and nephropathy. Mt. Sinai Medical Journal, 53: 254-289.
  82. Blanchette-Mackie, E.J., Wetzel, M.G., Chernick, S.S., Paterniti, J.R., Brown, W.V. and Scow, R.O. 1986. Effect of combined lipase deficiency (cld/cld) on ultrastructure on tissues in mice:

- diaphragm, heart, brown adipose tissue, lung and liver. Lab Invest., 55: 347-362.
83. Rubinstein, A., Gibson, J.C., Ginsberg, H.N. and Brown, W.V. 1986. In vitro metabolism of apolipoprotein E. Biochim. Biophys. Acta, 879: 355-361.82.
  84. Ginsberg, H.N., Le, N.-A., Wang-Iverson, P., Gibson, J.C., Rubinstein, A., Goldberg, I.J., Norum, R.A. and Brown, W.V. 1986. Apolipoprotein B metabolism in subjects with deficiency of apolipoprotein C-III and A-I: Evidence that apolipoprotein C-III inhibits lipoprotein lipase in vivo. J. Clin. Invest., 78: 1287-1295.
  85. Goldberg, I.J., Le, N.-A., Leeman, B., Ginsberg, H.N. and Brown, W.V. 1986 Evidence for kinetic heterogeneity of low density lipoprotein in the cynomolgus monkey. Biochim. Biophys. Acta 879:179-185.
  86. Brown, W.V. Dujovne, C.A., Farquhar J.W., Feldman E.B., Grundy S.M., Knopp R.H., Lasser N.L., Mellies M.J., Palmer R.H., Samuel Paul, Schonfeld Gustav and Seperko H.R. 1986. Effects of Fenofibrate on Plasma Lipids: Double blind, Multicenter Study in Patients with Type IIA or IIB Hyperlipidemia. Arteriosclerosis 6:680-678.
  87. Brown, W.V. 1987 Potential Use of Fenofibrate and Other Fibric Acid Derivatives in the Clinic. Am. J. Med.,83:85
  88. Bloomgarden, Z., Karmally, W., Metzger, M.J., Brother, M., Nechemias, C., Faierman, D., Ginsberg, F.,Rayfield, E. and Brown, W.V. 1987. A randomized controlled trial of diabetic patient education: Improved knowledge and behavior without improved metabolic status. Diabetes Care, 10:3 263-272.
  89. Gibson, J.C., Brown, W.V. 1988. Effect of lipoprotein lipase and hepatic triglyceride lipase activity on the distribution of apolipoprotein E among the plasma lipoproteins. Atherosclerosis, 73:45-55.
  90. Oka, K. Wang-Iverson, P., Paterniti, J. and Brown, W.V. 1989. Interaction of Lipoprotein Lipase with Heparin. Ann. NY Acad. Sci., 556: 173-180.
  91. Oka K., Yuan J.G., Senda M., Masibay A.S., Qasba P.K., Masuno H., Scow R.O., Paterniti J.R. Jr, Brown W.V. 1989. Expression of lipoprotein lipase gene in combined lipase deficiency. Biochim Biophys Act 1008:351-354.
  92. Oka K., Tkalcevic G.T., Stocks J., Galton D.J., Brown W.V. 1989. Nucleotide sequence of Pvu II RFLP site at the human lipoprotein lipase (LPL) gene locus. Nucl Acids Res 16:675.
  93. Brown, W. V. 1989. Review of Clinical Studies of Fenofibrate in Combination with Currently Approved Lipid-Lowering Drugs. Cardiology;76 (suppl. 1):45-54
  94. Brown, W. V. 1989. Treatment of hypercholesterolaemia with fenofibrate: a review. Current Medical Research Opinion 11: 321.

95. Nakano, T. Tucker, H., Oka, K. and Brown, W.V. 1990. A simple semi-dry capillary transfer of DNA. Biotechniques 8:2 173-174.
96. Oka, K., Tkalcevic, G.T., Brown, W.V., et al. 1991. Structure and polymorphic map of human lipoprotein lipase gene. Biochim. Biophys. Acta. 1049(1):21-26.
97. Hunninghake, D., Knopp, R., Schonfeld, G., Goldberg, A., Brown, W.V. et al. 1990. Efficacy and Safety of Pravastatin in Patients with Primary Hypercholesterolaemia. Atherosclerosis 85:81-89.
98. Oka, K., Nakano, T., Tkalcevic, G., Scow, R., and Brown, W.V. 1991. Molecular cloning of mouse hepatic triacylglycerol lipase; gene expression in combined lipase-deficient (cld/cld) mice. Biochim. Biophys. Acta, 1089:13-20.
99. Mishra, L., Le N-A., Brown, W. V., Mezey, E. 1991. Effect of Acute Intravenous Alcohol on Plasma Lipoproteins in Man. Metabolism, 4:1128-1130.
100. Ishimura-Oka, K., Semenkovich, C.F., Faustinella, F., Goldberg, I.J., Shachter, N., Smith, L.C., Coleman, T., Hide, W.A., Brown, W.V., Oka, K., Chan, L. 1992. A missense (Asp<sup>250</sup>→Asn) mutation in the lipoprotein lipase gene in two unrelated families with familial lipoprotein lipase deficiency. J Lipid Res, 33:745-754
101. Stamler, J., Stamler, M.A., Brown, W.V., Gotto, A.M., et.al.1993. Serum Cholesterol: Doing the Right Thing; Circulation:88;4:1954-1960.
102. Hunninghake, D.B., Miller, V.T., Kinosian, B., Brown, W.V., Howard W.J. 1994. Hypocholesterolemic Effects of a Dietary Fiber Supplement. American Journal of Clinical Nutrition; 59:1050-1054.
103. Hunninghake, D.B., Miller, V.T., LaRosa, J.C., Kinosian, B., Brown, W.V., Howard, J. 1994. Long-Term Treatment of Hypercholesterolemia with Dietary Fiber. American Journal of Med:97:504-508.
104. Brown, W. V., Kashyap, M.L. 1995. Proposition: Low HDL-C Should Be Treated (Pro/Con). Coronary Artery Disease:Index and Reviews;1:2:4,18.
105. Weintraub WS, Wenger, NK, Parthasarathy S. Brown WV. 1996. Hyperlipidemia versus iron overload and coronary artery disease: yet more arguments on the cholesterol debate. Journal of Clinical Epidemiology 49:1353-1358.
106. Bakker-Arkema, R.G., Davidson, M.H., Goldstein, R.J., Davignon, J., Isaacsohn, J.L, Weiss, S.R., Leonard, M.K., Brown, W.V., Miller, V.T., Shurzinske, L.J., Black, D.M. 1996. Efficacy and Safety of a New HMG-CoA Reductase Inhibitor in Patients with Hypertriglyceridemia. JAMA;275:128-133.
107. Li, X., Innis-Whitenhouse, W., Brown, W.V., Le, N-A. 1997. Protocol for the preparation of a sedimental linear polyacrylamide gradient gel: simultaneous determination of Lp(a), LDL and HDL particle sizes. Journal of Lipid Research; Vol 38;2603-



- 2614.
108. Frank, E., Rothenberg, R., Brown, W.V., Maibach, H. 1997. Basic Demographic and Professional Characteristics of US Women Physicians. West J Med;166:179-184.
  109. Harrison DG, Brown WV, Raggi P. Enhanced hype. Am J Cardiol. 2008 Aug1;102(3):368-9.
  110. Gutin, B., Owens, S., Allison, J., Ferguson, M., Moorehead, S., Le, N-A., Brown, W,V. Georgia Prevention Institute, Medical College of Georgia, Augusta, GA and Emory University School of Medicine, Atlanta, GA. 1997. Visceral Adipose Tissue is Inversely Related to LDL Particle Size in Obese Children. Medicine and Science in Sports and Exercise; 29:S86.
  111. Weingand, K.W., Le, N-A, Kuzmak, B.R., Brown W.V., Daggy, B.P., Tatu, A.M., Howard, B.V., Howard, J.W. 1997. Effects of Psyllium on Cholesterol and Low-Density Lipoprotein Metabolism;4:141-150.
  112. McCormick LS, Black DM, Waters D, Brown WV, PittB 1997. Rationale, design and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT). American Journal of Cardiology 80:1130-1133.
  113. Li X, W Innis-Whitehouse, WV Brown and N-A Le 1997. Simultaneous determination of Lp(a), LDL and HDL particle sizes by segmental non-denaturing gradient gel electrophoresis. J Lipid Res. 38: 2603-2614.
  114. Innis-Whitehouse W, X Li, WV Brown and N-A Le 1998. An efficient chromatographic system for lipoprotein fractionation using whole plasma. J Lipid Res 39: 679-690.
  115. Pitt B, Waters D, Brown WV, vanBoven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS. 1999. Aggressive lipid-lowering compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment (AVERT) Investigators. N Eng J Med 341:70-76.
  116. Breyers ED, N-A Le, X Li, D Martinson, and WV Brown 1999. Apolipoprotein C-III displacement of apoE from VLDL: Effect of particle size. J Lipid Res 40: 1875-1882.
  117. Le N-A, W Innis-Whitehouse, X Li, R Bakker-Arkema, D Black, and WV Brown 2000. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: Effect of atorvastatin. Metabolism. 49: 167-177.
  118. Le N-A, X Li, K Sung, and WV Brown 2000. Evidence for the in vivo generation of oxidatively modified Epitopes in patients with documented coronary artery disease. Metabolism. 49: 1271-1277.
  119. Anderson, J.W., Davidson, M.H., Blonde, L., Brown, W.V., Howard, W.J., Ginsberg, H., Allgood,

- L.D., Weingand, K.W., 2000: Long-Term Cholesterol-lowering Effects of Psyllium as an Adjunct to Diet Therapy in the Treatment of Hypercholesterolemia. *The American Journal of Clinical Nutrition*, 71: 1433-1438.
120. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R. for the Rosuvastatin Study Group. 2002 Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. *Am Heart J*; 144:103
121. Blasetto J, MPH, Stein E, Brown WV, Chitra R, Raza A. 2003. Efficacy of Rosuvastatin Compared with Other Statins at Selected Starting Doses in Hypercholesterolemic Patients and in Special Population Groups. *American Journal of Cardiology*. 91: 3C-10C
122. Sprecher, Dennis L. MD, Timothy R. Watkins, MD, W. Virgil Brown MD, Hanna B. Rubins MD, MPH, Ernst J. Schaefer, MD 2003. Importance of High-Density Lipoprotein Cholesterol and Triglyceride Levels in Coronary Heart Disease. *American Journal of Cardiology*. 91: 575-80.
123. Willens, Howard J. MD, Warren Davis, MD, David M. Herrington, MD, Karen Wade, MS, Karen Kesler, PhD, Steve Malton, MD, W.V. Brown, MD, JHC Reiber, PhD, and Jeffrey K. Raines, PhD 2003. Relationship of peripheral arterial compliance and standard cardiovascular risk factors. *Vascular and Endovascular Surgery*. 37:197-206
124. Breyer, Emelita D., Sarah Howard, Neeta Raje. Stuart Allison, Robert Apkarian, W. Virgil Brown, Joost K. Study of lipid and apolipoprotein binding interactions using vesicle affinity capillary electrophoresis. *Anal Chem*. 2003 Oct 1; 75 (19) :5160-9. PubMed PMID:14708791.
125. Herrington, David M. MD, MHS, Karen Kesler PhD, J.H.C. Reiber, PhD, Warren Davis, MD, W. Virgil Brown, MD, Ronald Helms PhD, Stephen M. Mallon MD, and Jeffrey Raines, PhD 2003. Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease. *American Heart Journal*. 146:662-667.
126. Gradek, W. Quinten MD, Matthey T. Harris, MD, Najat Yahia, PhD, Warren W. Davis, MD, Ngoc-Anh Le, PhD, W. Virgil Brown, MD 2004. Polyunsaturated Fatty Acids Acutely Suppress Antibodies to Malondialdehyde (MDA) Modified Lipoproteins in Patients with Vascular Disease. *American Journal of Cardiology*. 93:881-885.
127. Klein, Richard L., M. Brent McHenry, Kerry H. Lok, Steven J. Hunter, Ngoc-Anh Le, Alicia J. Jenkins, Deyi Zheng, Andrea Semler, W. Virgil Brown, Timothy J. Lyons, W. Timothy Garvey, and the DCCT/EDIC Research Group 2004. Apolipoprotein C-111 protein concentration and gene polymorphisms in Type I diabetes: Associations with microvascular disease complications in the DCCT/EDIC cohort. *Metabolism*. 53:1296-304.
128. Herrington DM., Brown WV, Mosca L, Davis W, Eggleston B, Hundley WG, MD; Raines J.

2004. Relationship Between Arterial Stiffness and Subclinical Aortic Atherosclerosis. Circulation. 110:432-437.
129. Saliashvili G, Davis W, Harris M, Le NA, Brown, WV. 2004 Simvastatin Improves Arterial Compliance in High Risk Patients. Vascular and Endovascular Surgery 38(6); 519-123.
  130. Pasternak Richard C, MD, McKenney James M, PharmD, Brown, W. Virgil, MD, Cohen Jerry, MD, Cahill E. 2004. Understanding physician and consumer attitudes about cholesterol management: Results from the National Lipid Association (NLA) surveys. Am J Cardiol. 94; (9A):9F-15F
  131. McKenney JM, PharmD, Brown W Virgil, MD, Cohen J, MD, and Cahill E. 2004 The NLA survey of consumers, physicians and pharmacists about an over-the-counter statin in the US: Is this a good idea? Am J Cardiol. 94; (9A); 16F-21F.
  132. McKenney JM, Bradberry JC, Talbert RL, Cahill E, and BrownW Virgil. 2004 National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statin therapy, and pharmacists' services. J AM Pharm Assoc. 44:562-568.
  133. Klein RL. McHenry MB. Lok KH. Hunter SJ. Le NA. Jenkins AJ. Zheng D. Semler A. Page G. Brown WV. Lyons TJ. Garvey WT. DCCT/EDIC Research Group. 2005 Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. Journal of Diabetes & its Complications. 19(1):18-25.
  134. Le NA. **Brown** WV. Davis WW. Herrington DM. Mosca L. Homma S. Eggleston B. Willens HJ. Raines JK. 2005 Comparison of the relation of triglyceride-rich lipoproteins and muscular artery compliance in healthy women versus healthy men. American Journal of Cardiology. 95(9):1049-54.
  135. Willens HJ. Chirinos JA. Brown WV. Davis WW. Herrington DM. Mosca L. Homma S. Moussa M. Walker G. Raines JK. 2005 Usefulness of arterial compliance in the thigh in predicting exercise capacity in individuals without coronary heart disease. American Heart Journal . 96(2):306-310.
  136. Rimland D. Guest JL. Hernandez I. Del Rio C. Le NA. Brown WV. 2005 Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins. HIV Med. 6(5):326-33.
  137. Rimland D. Guest, JL. Hernandez-Ramos, I. del Rio C. Le NA. Brown, WV. 2006 Antiretroviral Therapy in HIV-Positive Women Is Associated with Increased Apolipoproteins and Total Cholesterol. J Acquir Immune Defic Syndr 42:307-313.
  138. Brown WV. 2006 Different definitions of the metabolic syndrome and risk for

- recurrent cardiovascular disease. *Nature Clinical Practice Endocrinology & Metabolism*. 2(9):492-3.
139. Harris MT, Davis WW, Le NA, Eggleston B, Austin GE, Moussa M, Brown WV. 2007. Free oxygen radicals in whole blood correlate strongly with high sensitivity C-reactive protein. *J Clin Lipidology* 1(6):593-598
  140. Foody JM, Brown WV, Zieve F, Adewale AJ, Flaim D, Lowe RS, Jones-Burton C, Tershakovec AM. 2010. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults  $\geq 65$  years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). *Am J Cardiol*. 106:1255-63.
  141. Fruchart JC, Sacks FM, Hermans MP; International Steering Committee of R(3)i. 2010. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). *Curr Med Res Opin*. Aug;26(8):1793-7.
  142. Ginsberg HN, Brown WV. 2011. Apolipoprotein CIII: 42 years old and even more interesting. *Arterioscler Thromb Vasc Biol*. Mar;31(3):471-3
  145. Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT, Sniderman AD, Toth PP, Tsimikas S, Ziajka PE, Maki KC, Dicklin MR. 2011. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. *J Clin Lipidol*. 5:338-67.
  146. Beisswenger PJ, Brown WV, Ceriello A, Le NA, Goldberg RB, Cooke JP, Robbins DC, Sarwat S, Yuan H, Jones CA, Tan MH; IOOI Study Investigators. 2011. Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor  $\alpha$  are attenuated by prandial + basal insulin in patients with Type 2 diabetes. *Diabet Med*. 28:1088-95
  147. Tanya N. Turan<sup>a</sup>, Mike J. Lynn<sup>b</sup>, Azhar Nizam<sup>b</sup>, Bethany Lane<sup>b</sup>, Brent M. Egan<sup>a</sup>, Ngoc-Anh Le<sup>b,c</sup>, Maria F. Lopes-Virella<sup>a</sup>, Kathie L. Hermayer<sup>a</sup>, Oscar Benavente<sup>d</sup>, Carole L. White<sup>e</sup>, W. Virgil Brown<sup>b,c</sup>, Michelle F. Caskey<sup>a</sup>, Meghan R. Steiner<sup>a</sup>, Nicole Vilardo<sup>f</sup>, Andrew Stufflebean<sup>a</sup>, Colin P. Derdeyn<sup>g</sup>, David Fiorella<sup>h</sup>, Scott Janis<sup>i</sup>, and Marc I. Chimowitz, 2012, Rationale, Design, and Implementation of Aggressive Risk Factor Management in the SAMMPRIS Trial. *Circulation: Qual and Outcomes*. 5:e51-e60
  148. Koola MM, Brown WV, Qualls C, Cuthbert B, Hollis JP, Kelly DL, Le N-A, Raines J, Duncan EJ. 2012. Reduced arterial compliance in patients with psychiatric diagnoses. *Schizophrenia Research*;137:251-253.
  149. Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid

Association Harold E. Bays, MD, FNLA, Chair\*, Peter P. Toth, MD, PhD, FNLA, Co-Chair Penny M. Kris-Etherton, PhD, RD, FNLA, Co-Chair, Nicola Abate, MD, Louis J. Aronne, MD, W. Virgil Brown, MD, FNLA, J. Michael Gonzalez-Campoy, MD, PhD, Steven R. Jones, MD, FNLA, Rekha Kumar, MD, Ralph La Forge, MSc, FNLA, Varman T. Samuel, MD, PhD.. 2013 J Clin Lipid; 7:304-383.

150. Le N-A, Diffenderfer MR, Thongtang N, Ooi EMM, Barrett PHR, Horvath KV, Dolnikowski GG, Asztalos BF, Schaefer EJ, and Brown WV. 2013 Dose-Dependent Effects of Rosuvastatin on the Metabolism of Apolipoproteins B-100 and A-I in Subjects with Combined Hyperlipidemia. (IN Press)

## **BOOK CHAPTERS, EDITORIALS AND INVITED PAPERS**

1. Levy, R.I., Quarfordt, S.H., Brown, W.V. et al. 1969. The efficacy of clofibrate (CPIB) in familial hyperlipoproteinemia. In "Drugs Affecting Lipid Metabolism" in: Advances in Experimental Medicine and Biology, Vol. 4, eds., Holmes, W.L., Carlson, L.A. and Paoletti, R. (Plenum Publishing Corp., New York).307-325.
2. Ehnholm, C., Shaw, W., Brown, W.V. et al. 1973. Characterization of a highly purified human postheparin lipase. Proceedings of the Third International Symposium on Atherosclerosis. West Berlin, Germany.
3. Brown, W.V. and Baginsky, M.L. 1974. Some functional aspects of apolipoproteins: ApoLp-Ala inhibition of lipoprotein lipase and deinhibition by monoolein. Hormone and Metabolic Research. Lipid Metabolism, Obesity and Diabetes Mellitus in Impact on Atherosclerosis. International

Symposium April, 1972. (George Thieme Publishers)11-16.

4. Brown, W.V., Shaw, W. et al. 1976. Lipases and Lipoproteins. In: Lipoprotein Metabolism, Ed., Greten, H. (Springer-Verlag, Germany) 2-6.
5. Augustin, J., Freeze, H., Boberg, J. and Brown, W.V. 1976. Human postheparin plasma lipolytic activities. In: Lipoprotein Metabolism, Ed., Greten, H. (Springer-Verlag, Germany) 7-12.
6. Augustin, J., Middelhoff, G. and Brown, W.V. 1976. Metabolismus der lipo-proteine. In: Fettstoffwechsel, (Springer-Verlag, Germany) pp 219-264.
7. Greten, H. and Brown, W.V. 1976. Hyperlipoproteinemia, Type I. In: Fettstoffwechsel, (Springer-Verlag, Germany) 265-273.
8. Brown, W.V., Baginsky, M.L. and Ehnholm, C. 1977. Primary Type I and V hyperlipoproteinemia. In: Hyperlipidemia, Diagnosis and Therapy, Eds., Rifkind, B. and Levy, R.I. (Grune & Stratton, Inc.) 93-112.
9. Wilson, D. and Brown, W.V. 1977. Lipids and lipoproteins in diabetes mellitus. In: Advances in Modern Nutrition, Vol II, Eds., Katzen, H. and Mahler, R. 127-186.
10. Baginsky, M.L., Wu., F. and Brown, W.V. 1978. Assay of lipoprotein lipase in postheparin plasma after suppression of the hepatic triglyceride lipase with sodium dodecyl sulfate. In: The Lipoprotein Molecule, Ed., Peters, H.; Proc. of a NATO Advance Study Inst. Meeting - Brugge, Belgium (Plenum Publ. Co., New York) 15: 169-182.
11. Wang-Iverson, P., Jaffe, E.A. and Brown, W.V. 1979. Triglyceride hydrolysis by lipoprotein lipase bound to endothelial cells in culture. In: Atherosclerosis V, Eds., Gotto, A.M., Smith, L.C. and Allen, B. (Springer-Verlag, New York) 375-378.
12. Brown, W.V., Wang-Iverson, P. and Paterniti, J.R. 1981. Heparin, lipoproteins and lipoprotein lipase. In: The Chemistry and Biology of Heparin, Ed., Lundblad, R. (Elsevier, North Holland, New York) 175-185.
13. Brown, W.V. and Ginsberg, H. 1982. Hyperlipoproteinemia and diabetes. In: Diabetes Mellitus and Obesity, Ed., Brodoff and Bleicher (Williams and Wilkins, New York) pp 192-199.
14. Le, N.-A., Ginsberg, H. and Brown, W.V. 1982. Compartmental model for the study of apoprotein-B catabolism in man. In: Lipoprotein Kinetics and Modeling, Eds., Berman, M., Grundy, S.M. and Howard, B.V. (Academic Press, New York) 121-137.
15. Brown, W.V. 1982. Diabetes mellitus and arteriosclerosis: Risk factors, mechanisms and management. in: Diabetes Management in the Eighties, Ed., Peterson, C.M. (Praeger Publishers, New York) 40-55.
16. Grundy, S.M., Bilheimer, D., Blackman, H., Brown, W.V. et al. 1982. Rationale of the Diet Heart State of the American Heart Association. Circulation, 65: 839A-854A.

17. Goldberg, I.J., Le, N.-A., Paterniti, J.R., Ginsberg, H.N., Lindgren, F.T. and Brown, W.V. 1983. The role of hepatic triglyceride lipase in primates. Atherosclerosis VI, **3**: 233-241.
  18. Brown, W.V. 1983. Hyperlipoproteinemia. In: Current Therapy in Endocrinology, 1983-1984, Eds., Krieger, D.T. and Barden, C.W. (B.C. Decker, Inc., Philadelphia) 233-239.
  19. Brown, W.V. Ginsberg H, Karmally W. 1984. Diet and the decrease of coronary heart disease. Am J Cardiol 54:27C-29C.
  20. Brown, W.V. Goldberg, IJ, Ginsberg HN. 1984. Treatment of common lipoprotein disorders. Progress in Cardiovascular Diseases, 27: 1-20.
  21. Brown, W.V et al. 1984. Diet and decline of coronary heart disease. In: Status and Perspectives on the Role of Cholesterol, Ed., Levy, R.I. (Science and Medicine, New York).
  22. Boyd, K., Brown, W.V. et al. 1985. Cholesterol Counts: Steps to Reduce Your Patient's Blood Cholesterol Levels. U.S. Department of Health and Human Services, Public Health Service National Institutes of Health, 85:2599
  23. Grundy, S.M., Arky, R., Bray, G.A., Brown, W.V. et al. 1985. Coronary risk factor statement for the American Public. A statement of the nutrition committee of the American Heart Association. Circulation, 5: 678A-683A.
  24. Ginsberg, H.N., Brown, W.V. and Goldberg, I.J. 1985. Treatment of common lipoprotein disorders. Primary Cardiology, **11**: 152-166.
  25. Le, N.A., Bukberg, P.R., Ginsberg, H.N., Gibson, J.C. and Brown, W.V. 1986. Direct determination of apoC-III specific activity using immunoaffinity chromatography. Methods of Enzymology, 129:457-468.
- Book)**
26. Gibson, J.C., Rubinstein, A., Ginsberg, H.N. and Brown, W.V. 1986. Isolation of apoE containing lipoproteins by affinity chromatography. Methods in Enzymology, Eds., Albers, J. and Segrest, J. (Academic Press, New York) 186-200.
  27. Le, N.-A., Ramakrishnan, R., Dell, R.B., Ginsberg, H. and Brown, W.V. 1986. Kinetic analysis of specific radioactivity data. Methods of Enzymology, 129:384-394.
  28. Ginsberg, H. Rubinstein, A. and Brown, W.V. 1986. Medical Complications of Accutane (Isotretinoin, 13 cis Retinoic Acid). Dermatologic Clinics, 4:183-190.
  29. Brown, W. V. 1987 Introduction: Fenofibrate, a Third-Generation Fibric Acid Derivative. Am. J. Med., 83:85
  30. Brown, W.V. and Ginsberg, H. 1987. Classification and diagnosis of the hyperlipidemias. In: Hypercholesterolemia and Arteriosclerosis, Eds., Steinberg, D. and Olefsky, J. (Churchill Livingstone) 143-168
  31. Smith, D.A., Karmally, W. and Brown, W.V. 1987. Treating hyperlipidemia, Part I: Whether and when in the elderly. Geriatrics, 42:33-44.

32. Smith, D.A., Karmally, W. and Brown, W.V. 1987. Treating hyperlipidemia, Part II: Making dietary control work in the elderly. Geriatrics, 42:39-43.
33. Smith, D.A., Karmally, W. and Brown, W.V. 1987. Treating hyperlipidemia, Part III: Drug therapy. Geriatrics, 42: 55-62.
34. Howard, W.J. and Brown, W.V. 1988. Pharmacologic Therapy of Hypercholesterolemia. Current Opinion in Cardiology, 3:525-541.
35. Brown, W.V. 1988. Focus on Fenofibrate. Hospital Practice Symposium Supplement, 23:31-40.
36. Brown, W.V. 1988. The cholesterol hypothesis and the value of intervention. Journal of the American Osteopathic Association 88:859-864.
37. Brown, W.V. 1988. Using Total Plasma Cholesterol Values. Medical Management Dynamics 6:9-11.
38. Fischer, L. and Brown, W.V. 1989. Fischer/Brown Low Cholesterol Gourmet Cookbook Acropolis Books, Washington, D.C.
39. Grundy, SM, Brown WV, Dietschy JM, Ginsberg H, Goodnight S, Howard B, LaRosa JC, McGill HC. 1989. AHA Conference Report on Cholesterol. Basis for dietary treatment. Circulation 80:729-734.
40. Brown, W. V. 1989. Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs. Cardiology. 76(Suppl)1:45-51
41. Brown, W. V. 1989. Treatment of hypercholesterolaemia with fenofibrate: a review. Current Med Res and Opinion. 11:321-330.
42. Brown, W.V. 1990. Clinical Trials Including an Update on the Helsinki Heart Study. Am. J. Card. 66:6 11A-15A
43. Brown, W.V. 1990. Fibric Acid Derivatives. J.of Drug Dev.3:suppl. 1
44. Brown W.V. 1990. Dietary Recommendation to prevent coronary heart disease. In: Atherosclerosis II: Recent progress in atherosclerosis research: the second Saratoga International Conference on Atherosclerosis in Towada. Ed. Lee, K.T., Onodera, K. and Tanaka, K. Annals N.Y. Acad. of Sciences 598:376-388.
45. Brown, W.V. 1990. Fats and Cholesterol. In: The Mount Sinai School of Medicine Complete Book of Nutrition, Ed. Herbert, V. and Subak-Sharpe, G.J. St. Martin's Press, New York, NY. 58-88.
46. Brown, W.V. 1990. Nutrition and Heart Disease In: The Mount Sinai School of Medicine Complete Book of Nutrition. Ed. Herbert, V. and Subak-Sharpe, G.J. St. Martin's Press, New York, NY. 431-468.



47. Brown, W.V. and Howard, W.J. 1990. Treatment of lipoprotein disorders. In: Preventive Aspects of Coronary Heart Disease. Eds. Frohlich, E. and Brest, A. F.A. Davis Co. Philadelphia, PA. 157-176.
48. Brown, W.V. and Howard, W.J. 1990. Treatment of lipoprotein disorders. Cardiovascular Clinics. 20:157-176.
49. Merrill, R.A., McGill, H.C., Jr., Campbell, T.C., Endman, J.W., Gregory, J.F., III, Hall, R.L., Hammonds, T.M., Halsing, E., Schmidt, A.M., Sims, L.S., Stern, J.S., Wellman, N.S and Gussow, J.D. and Brown, W.V. 1990. Nutrition Labelling: Issues and directions for the 1990's. Report of a study by the Committee on the Nutritional Components of Food Labelling, Food and Nutrition Board, Institute of Medicine, National Academy of Sciences. Eds. Porter, D.V. and Earl, R.O.
50. Brown, W.V., Brunton, S.A., Denke, M.A. 1990. Elevated lipids, older patients. Patient care. 157-177
51. Brown, W.V. 1990. Review of clinical trials: proving the lipid hypothesis. Eur. Heart J. Supplement H: 15-20.
52. Brown, W.V., Field, L., and Howard, W.J. 1991 Nicotinic Acid and Its Derivatives. In: Drug Treatment of Hyperlipidemia. Ed. Rifkind, B. Marcel Dekker, New York, NY. 189-213
53. Brown, W.V. 1992. The Fibric Acid Derivatives. In: Office Management of Lipid Disorders. Ed. Larosa, J. Healthcare Communications, Ft. Lee, NJ.
54. Brown, W.V. 1992. President's address to the 64<sup>th</sup> scientific sessions of the American Heart Association. Circulation. 85:1969-1971.
55. Brown, W.V. 1992. Breslow, J.L. Genetic Lipoprotein Abnormalities Producing High Blood Cholesterol. Heart Disease and Stroke. 1:405-407.
56. Brown, W.V. 1992. Lipoproteins: What, When, and How Often to Measure. Heart Disease and Stroke. 20-26.
57. Brown, W.V., Knopp, R.H, Corder, C.N., Dobs, A.S, Dujovne, C. 1992 et.al: Comparative Efficacy and Safety of Pravastatin and Cholestyramine Alone and Combined in Patients with Hypercholesterolemia; Pravastatin Multicenter Study Group II; Archives of Int. Medicine.
58. Brown, W.V., 1992. When Do We Treat Hypercholesterolemia? Clin. Cardiology. 15:10-14.
59. Brown, W.V., Le, N.-A., Gravanis, M.B. 1993. Mosby. Atherogenesis in Pathology; Chapter 1 in Cardiovascular Disorders: Pathogenesis and Pathophysiology. Ed. Gravanis, M.B. Mosby. 1-13.
60. Brown, W.V. Editor. 1993. A Symposium: Hydroxymethylglutaryl Coenzyme a Reductase Inhibition: Fluvastatin, a Clinical Investigators' Update. American Journal of Cardiology;73:14.
61. Pearson TA, Brown WV, Donato K, Franklin FA Jr, Luepker RB, McBride PE, Mullis RM, Scott

- LW, Shannon B, Shekelle RB et al. 1993 Lipids. Workshop IV. AHA Prevention Conference III. Behavior change and compliance: keys to improving cardiovascular health. Circulation 88:1397-1401.
62. Brown, W.V. 1994. Lipoprotein Disorders in Diabetes Mellitus. In: The Medical Clinics of North America;78:143-161.
  63. Brown, WV. 1994. Hydroxymethylglutaryl conenzyme A reductase inhibition: fluvastatin, a clinical investigators' update. American Journal of Cardiology. 73:1D-2D
  64. Brown, W.V., Le, N-A. 1995. Lipoprotein(a) Should Be Measured and Treated as a Cardiovascular Risk Factor. Coronary Artery Disease; Index and Reviews;1:4-6.
  65. Brown, W.V. 1995. Niacin As A Novel Therapeutic Agent: Indications, Effectiveness, and Safety. Postgraduate Medicine; 88:185-193.
  66. Le, N-A, Brown, W.V., Le, N-A. 1996. Triglyceride-rich lipoproteins. Atlas of Heart Diseases 5:1-5. Ed. W.V. Brown, Current Medicine.
  67. Brown, W.V. Editor. 1996. Atlas of Heart Disease, Vol X: Atherosclerosis: Risk Factors and Treatment
  68. Brown, W.V., Le, N-A, Robertson, D.G. 1996. Lipid-lowering drugs. Heart Disease Management: A Pharmacologic Approach, Eds J. Kupersmith and P.C. Deedwania. Williams & Wilkins. 41-79.
  69. Brown, W.V. 1996. Blood Lipid Control in the Treatment of Coronary Atherosclerotic Heart Disease. Resident and Staff Physician. Supplement.
  70. Brown WV. 1997. Hypercholesterolemia in the United States: how far have we come?.] American Journal of Medicine. 102(2A):3-6
  71. Brown, W.V., editor. 1997. Epidemiology and treatment of hypercholesterolemia: Where are we today. American Journal of Medicine.102.
  72. Brown, WV 1998 Impact of dyslipidaemia. Lessons from the clinical trials. Pharmacoeconomics 14 (Suppl) 3:1-9.
  73. Brown WV, Jacobson TA. 2000 The Management of Lipoprotein Disorders, in Cardiology in Primary Care. Edited by W.T. Branch, Jr., et al The McGraw-Hill Companies Inc., 201-221.
  74. Brown WV, 2000. Risk Factors for Vascular Disease in Patients with Diabetes Diabetes, Obesity & Metabolism. 2
  75. Brown WV, Davis W. 2000 Special Problems in Hyperlipidemia Therapy, Textbook of Cardiology, Case Reports. 1-7. Mosby International, UK
  76. Brown WV, Davis W. 2000. "Diabetes mellitus type II", Ch. 1.04a in Special problems in the

- Prevention of Cardiovascular Disease in Women, Textbook of Cardiology Case Reports. 1-7. Mosby International, UK
77. Brown WV. 2000. "Cholesterol Lowering in Atherosclerosis"; The American Journal of Cardiology. 86 86(4B):29H-32H
  78. Brown, WV. 1989. Treatment of hypercholesterolaemia with fenofibrate: a review. Current Medical Research Opinion 11: 321.
  79. Brown WV. 2000. "The benefit of aggressive lipid lowering"; Atherosclerosis Supplements 1 1519 Elsevier Science Ireland Ltd.
  80. Brown WV. 2000. Cholesterol lowering in arteriosclerosis. American Journal of Cardiology. 86:29H-34H
  81. Brown WV. et al., 2001. Theoretical Applications of Statin Therapy: Beyond Coronary Disease Circulation series Atherosclerosis From Bench to Bedside
  82. Brown WV. 2001. What are the priorities for managing cholesterol effectively?. American Journal of Cardiology. 88(4A):21F-4F,
  83. Brown WV. 2001. New Therapies on the Horizon (Symposia Proceedings) Supplement to The Am. J. of Managed care, Atherosclerosis: Achieving Optimal Outcomes in Statin Therapy. 7: S148-151.
  84. Brown WV. 2001. "Debate: How low should LDL cholesterol be lowered for optimum prevention of vascular disease?" Viewpoint: below 100 mg/dl" in Current Controlled Trials in Cardiovascular Medicine, Editors-in-chief: Curt Furberg and Betram Pitt. 2: 12-15
  85. Brown WV. 2001. Statin Therapy in the New Millennium: Is There Room for Improvement? Clinical Cardiology. Supplement III 24: 8
  86. Brown WV. 2001 Therapies on the horizon for cholesterol reduction. Clinical Cardiology. 24(8 Suppl): III 24-7.
  87. Brown WV. 2002. Promising Therapies for Cholesterol Reduction. Managed Care Supplement Transforming Dyslipidemia Management 11(*Suppl 9*):10-4.
  88. Harris, M Davis, W. Brown, W. V 2003. Ezetimibe. Drugs of Today 39: 2993
  89. Brown, W.V. 2003. Benefits of statin therapy in patients with special risks: coronary bypass surgery, stable coronary disease and acute coronary syndromes. Clinical Cardiology, 26 4 Supple 3 III 1:3-8.
  90. Brown, W.V. 2003 Reaching goal: conquering the treatment gaps in dyslipidemia management. Clinical Cardiology. 26(4 Supple 3):III 1:2

91. Brown, W.V. Evidence supports aggressive treatment of low HDL cholesterol and triglycerides. Invited editorial. Cardiology Express Report.
92. Brown, W.V 2003. Cholesterol absorption inhibitors: defining new options in lipid management. The Journal of Clinical Cardiology. 26:259-64.
93. Brown, W.V. and Davis, W. 2003. Diabetes mellitus, Type II. Cardiology. Crawford and DiMarco, eds. Mosby International UK. Section 1, Chapter 5
94. Brown, V. and Davis, W. 2003. Child with hypercholesterolemia. Cardiology. Crawford and DiMarco, eds. Mosby International UK. Section 1, Chapter 9
95. Brown, V. and Davis, W. 2003. Menopausal Women. Cardiology. Crawford and DiMarco, eds. Mosby International UK. Section 1, Chapter 5.
96. Brown, V. and Davis, W. 2003. Transplant patient. Cardiology. Crawford and DiMarco, eds. Mosby International UK. Section 1, Chapter 9
97. Brown, V. and Davis, W. 2003. Elevated Lp(a). Cardiology. Crawford and DiMarco, eds. Mosby International UK. Section 1, Chapter 9
98. Brown, V. and Davis, W. 2003 Hypercholesterolemia in the elderly. Cardiology. Crawford and DiMarco, eds. Mosby International UK. Section 1, Chapter 9
99. Brown WV, MD, Davis W, MD, Harris M 2003. Implications of the heart protection study for reducing coronary events in high-risk patients. Current Arteriosclerosis Reports. 5:358-363
100. Brown, W.V. MD. 2003 Don't Lose Control The Lipid Spin. 1:2-5
101. Brown WV, Moussa M. 2003. Perspectives from the antihypertensive and lipid-lowering treatment to prevent heart attack trial-lipid-lowering trial and the Anglo-Scandinavian cardiac outcomes trial, lipid lowering arm. Current Opinion in Lipidology. 14(6):593-7.
102. Brown, W. Virgil MD 2004. Approaching the patient with concomitant lipid disorders. The Clinical Advisor.
103. Brown, W. Virgil MD. 2004. Managing Dyslipidemia - Multiple Patients and Multiple Approaches: Metabolic Syndrome, Familial Hypercholesterolaemia and Hypertension. European Heart Journal Supplement.
104. Brown, W Virgil MD. 2004 Pharmacological treatment of lipid disorders in diabetes. Int J Clin Pract. 58 (Suppl. 142);35-39.
105. Rifai N. Cooper GR. Brown WV. Friedewald W. Havel RJ. Myers GL. Warnick GR. 2004 Clinical Chemistry journal has contributed to progress in lipid and lipoprotein testing for fifty years. Clinical Chemistry. 50(10):1861-70.

106. Brown WV. 2004 Metabolic syndrome and risk of stroke. Clinical Cornerstone. 6 Suppl 3:S30-4.
107. Brown WV. 2004 The Current State of Cardiovascular Disease Risk-Reduction in the US. Should Consumers Be Given an OTC-Statin Option to Help Reduce Their CHD Risk? Exploring the Evidence National Lipid Association Monograph pp 3-10.
108. Brown WV. 2006. Is Hypertriglyceridemia a Risk Factor in Patients With Normal Cholesterol Levels? Cardiosource. On Line Newsletter of the Am. Coll. Cardiology.
109. Brown WV. 2006. A Change of Heart, BOOK REVIEW: Circulation; 113: e162 - e163.
110. Aronne LJ, Brown WV, Isoldi KK. Cardiovascular disease in obesity: A review of related risk factors and risk-reduction strategies. J Clin Lipidol. 2007 Dec;1(6):575-82.
111. Brown WV. 2007 From the Editor-in-Chief. J Clin Lipidol. Dec;1(6):561.
112. Brown WV. 2007 From the Editor-in-Chief. J Clin Lipidol. Oct;1(5):301.
113. Brown WV. 2007 From the Editor-in-Chief. J Clin Lipidol. Aug;1(4):225-6.
114. Brown WV. 2007 From the Editor-in-Chief. J Clin Lipidol. Jul;1(3):171.
115. Brown WV. 2007 From the Editor-in-Chief. J Clin Lipidol. May;1(2):97-9.
116. Brown, WV. 2007 High Density Lipoprotein and Transport of Cholesterol and Triglyceride in Blood. J Clin Lipidology. 1:7-19.
117. Brown WV. 2008 From the Editor-in-Chief. J Clin Lipidol. 2:1707.
118. Davis WW, Brown WV. 2008. Diabetes mellitus, Type II. Cardiology (2<sup>nd</sup> Edition). Crawford and DiMarco, eds. Mosby International UK.
119. Davis WW, Brown WV. 2008. Elevated Lp(a). Cardiology (2<sup>nd</sup> Edition). Crawford and DiMarco, eds. Mosby International UK.
120. Davis WW, Brown WV. 2008. Transplant Patients. Cardiology (2<sup>nd</sup> Edition). Crawford and DiMarco, eds. Mosby International UK.
121. Brown WV, Davis WW. 2008. Hypercholesterolemia in the Elderly. Cardiology (2<sup>nd</sup> Edition). Crawford and DiMarco, eds. Mosby International UK.
122. Brown WV, Davis WW. 2008. Post-Menopausal Women. Cardiology (2<sup>nd</sup> Edition). Crawford and DiMarco, eds. Mosby International UK.
123. Brown WV, Davis WW. 2008. Children with Hypercholesterolemia. Cardiology (2<sup>nd</sup> Edition)

Edition). Crawford and DiMarco, eds. Mosby International UK.

124. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. *Am J Cardiol.* 2008 Nov 17;102(10 Suppl):1K-34K.
125. Brown WV. From the Editor-in-chief. *J Clin Lipidol.* 2008 Dec;2(6):403.
126. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. 2008 Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. *Diab Vasc Dis Res.* Nov;5(4):319-35.
127. Brown WV. Safety of statins. 2008 *Curr Opin Lipidol.* Dec;19(6):558-62.
128. Brown WV, Clark L, Falko JM, Guyton JR, Rees TJ, Schonfeld G, Lopes-Virella MF. 2008 Optimal management of lipids in diabetes and metabolic syndrome. *J Clin Lipidol.* Oct;2(5):335-42.
130. Brown WV. 2008 From the Editor-in-Chief. *J Clin Lipidol.* 2:311.
131. Garelnabi MO, Brown WV, Le NA. 2008 Evaluation of a novel colorimetric assay for free oxygen radicals as marker of oxidative stress. *Clin Biochem.* 41:1250-4.
129. Brown WV. 2008 From the editor. *J Clin Lipidol.* 2:308.
130. Brown WV. 2008 From the Editor-in-Chief. *J Clin Lipidol.* 2:233.
131. Brown WV. 2008 From the Editor-in-Chief. *J Clin Lipidol.* 2:113.
132. Brown WV. 2008 From the Editor-in-Chief. *J Clin Lipidol.* 2 :67-8.
133. Brown WV. Microvascular 2008 complications of diabetes mellitus: renal protection accompanies cardiovascular protection. *Am J Cardiol.* 102:10L-13L.
134. Brown WV, Fletcher GF, Wilson PW. 2009 Using exercise to reduce risk. *J Clin Lipidol.* 3:360-7.
135. Brown WV. 2009 From the Editor-in-Chief. *J Clin Lipidol.* Dec ; 3 ( 6 ) : 357
136. Brown WV, Karmally 2009 W, Kris-Etherton P, Rudel LR. Discussion on dietary fat. *J*

Clin Lipidol. 3:303-14.

137. Brown WV. 2009 From the Editor-in-Chief. J Clin Lipidol. 3:299-300.
138. Brown WV, Brewer HB, Rader DJ, and Schaefer EJ. 2010 HDL as a treatment target. J Clin Lipidol. 4:5-16.
139. Brown WV, Brown AS, Raggi P, Sperling LS. 2009 Appropriate use of noninvasive vascular measures in the prevention of arterial disease. J Clin Lipidol. 3:250-61.
140. Brown WV. 2009 From the Editor-in-Chief. J Clin Lipidol. 3:241.
141. Brown WV, Fujioka K, Wilson PW, Woodworth KA. 2009 Obesity: why be concerned? Am J Med. 122:S4-11.
142. Brown WV, Goldberg AC, Guyton JR, Knopp RH. 2009 The use of niacin. J Clin Lipidol. 3:65-9.
143. Brown WV. 2009 From the Editor. J Clin Lipidol. Apr;3(2):61-2.
144. Brown WV. From the Editor: 2010 The disparity between the very strong performance of high-density lipoprotein (HDL) and the very weak effects of HDL-cholesterol as a risk factor. J Clin Lipidol. 4: 1.
145. Brown WV, Brewer HB, Rader DJ, and Schaefer EJ. 2010 HDL as a treatment target. J Clin Lipidol. 4:5-16.
146. Brown WV. 2010 Foreword: Risk of vascular disease development and recurrence. J Clin Lipidol. 4:77-8.
147. Brown WV, Wenger N, Bittner V, Brinton E. 2010 Assessing and addressing risk of cardiovascular disease in perimenopausal and early postmenopausal women. J ClinLipidol. 4:324-34.
148. Brown WV, Ballantyne CM, Jones PH, Marcovina S. 2010 Management of Lp(a). J Clin Lipidol. 4:240-7
149. Brown WV. From the Editor: 2010 Inflammatory markers and treatment of elevated LDL-C J Clin Lipidol. 4:237.
150. Brown WV, Myers GL, Sniderman AD, Stein E. 2010 Should we use apoB for risk assessment and as a target for treatment? J Clin Lipidol. 4:144-51.
151. Brown WV. 2010 Estimating risk and setting targets for treatment in the national effort to

- reduce cardiovascular diseases. Foreword. *J Clin Lipidol.* 4:139-41.
152. Brown WV, Wilson DP, Freemark M, Kwiterovich PO. 2010 The use of lipid-lowering drugs in children. *J Clin Lipidol.* 4:449-61.
  153. Brown WV, Goldberg RB, Lopes-Virella M, Reaven P. 2011 Reducing vascular disease risk in the type 2 diabetic patient. *J Clin Lipidol.* 5:3-11.
  154. Brown WV, Bays H, Davidson M, Goldberg A. 2011 Drugs in development for management of lipoprotein disorders. *J Clin Lipidol.* 5:66-75.
  155. Brown WV. 2011 From the editor. *J Clin Lipidol.* 5 :61-3.
  156. Brown WV. 2011 From the editor. *J Clin Lipidol.* 5:121
  157. Brown WV. 2011 From the editor. *J Clin Lipidol.* 5:247-8.
  158. Brown WV, Bakris G, Lerma E, Chertow, G. 2011 Assessment and management of vascular disease risk in patients with chronic kidney disease. *J Clin Lipidol.* 5:251-260
  159. Brown WV. 2011 Framingham Heart Study. *J Clin Lipidol.* 5:335.
  160. Brown WV. 2011 From the editor. *J Clin Lipidol.* 5:421.
  161. Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT, Sniderman AD, Toth PP, Tsimikas S, Ziajka PE, Maki KC, Dicklin MR. 2011 Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. *J Clin Lipidol.* 5:338-67.
  162. Brown WV, Bays H, Harris W, Miller M. 2011 Using omega-3 fatty acids in the practice of clinical lipidology. *J Clin Lipidol.* 5:424-33.
  163. Brown WV, Bays H, Harris W, Miller M. 2011 Using omega-3 fatty acids in the practice of clinical lipidology. *J Clin Lipidol* 5(6):424-33.
  164. Brown, WV. 2012 From the editor: Five years of growth for the journal. *J Clin Lipidol.* 6:1-2.
  165. Brown WV. 2012 From the editor: Medications that lower low-density lipoprotein (LDL) cholesterol and non-high-density lipoprotein (non-HDL) cholesterol.. *J Clin Lipidol.* 6:95.
  166. Brown WV, Brook R, Hemphill LC, Moriarty PM. 2012 The use of lipopheresis in the practice of clinical lipidology. *J Clin Lipidol* 6:98-104.



167. Brown WV. 2012 From the Editor: Important anniversaries for the NLA and for statins. *J Clin Lipidol.* 6(3):197.
168. Brown WV, Breslow J, Ballantyne C. 2012 Clinical use of genetic typing in human lipid disorders. *J Clin Lipidol.* 6(3):199-207.
169. Brown WV. 2012 From the Editor: What are the important questions for clinical trials? *J Clin Lipidol.* 6:299-300.
170. Brown WV. 2012 From the editor: the enigma of hypertriglyceridemia. *J Clin Lipidol.* 6:393-4.
171. Brown WV, Brunzell JD, Eckel RH, Stone NJ. 2012 Severe hypertriglyceridemia. *J Clin Lipidol.* 6:397- 408.
172. Brown WV. 2012 From the editor. *J Clin Lipidol.* 6:481-2.
173. Brown WV, Bays HE, Maki KC, Wild RA 2012 Planning a clinical trial. *J Clin Lipidol.* 6:484-95.
- 174.** Brown WV. 2013 From the editor: selling the benefit of drug therapy. *J Clin Lipidol.* 7:1-2
175. Brown WV, Jacobson TA, Braun LT. 2013 Achieving adherence to lipid-lowering regimens. *J Clin Lipidol* 7:4-13.
176. Brown WV. 2013 From the editor: Learning from defects. *J Clin Lipidol.* 7:91-2.
177. Brown WV. 2013 From the editor: NLA Scientific Sessions. *J Clin Lipidol* 7:185.
178. Brown WV. 2013 From the editor: What is Obesity?. *J Clin Lipidol* 7:289-290.
179. Brown WV, McNeal CJ, Gidding SS. 2013 Screening and management of cardiovascular risk factors in children. *J Clin. Lipidol* 7:390-398.
180. Brown WV, Rader DJ, Kane, J. 2013 JCL Roundtable: Diagnosis of severe familial hypercholesterolemia. *J Clin. Lipidol* 7:540-545.
181. Brown WV. 2013 From the Editor: The future of managing lipoprotein disorders. 7:535-538.